Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 334

The DOI matches its Crossref record.

Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status

Eisenhofer, Graeme, Lenders, Jacques W.M., Siegert, Gabriele, Bornstein, Stefan R., Friberg, Peter, Milosevic, Dragana, Mannelli, Massimo, Linehan, W. Marston, Adams, Karen, Timmers, Henri J., Pacak, Karel·2012·European Journal of Cancer

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2011.07.016

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 32

  1. Eisenhofer, 2004, Malignant pheochromocytoma: current status and initiatives for future progress, Endocr Relat Cancer, 11, 423, 10.1677/erc.1.00829 · DOI · Paper page
  2. Chrisoulidou, 2007, The diagnosis and management of malignant phaeochromocytoma and paraganglioma, Endocr Relat Cancer, 14, 569, 10.1677/ERC-07-0074 · DOI · Paper page
  3. Brouwers, 2005, Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma, Endocr Relat Cancer, 12, 263, 10.1677/erc.1.00913 · DOI
  4. Brouwers, 2006, Gene expression profiling of benign and malignant pheochromocytoma, Ann NY Acad Sci, 1073, 541, 10.1196/annals.1353.058 · DOI
  5. Strong, 2008, Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis, Surgery, 143, 759, 10.1016/j.surg.2008.02.007 · DOI · Paper page
  6. Suh, 2009, Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling, Ann Surg, 250, 983, 10.1097/SLA.0b013e3181b248bb · DOI
  7. Thouennon, 2010, Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival, Endocr Relat Cancer, 17, 637, 10.1677/ERC-10-0109 · DOI
  8. Waldmann, 2010, Microarray analysis reveals differential expression of benign and malignant pheochromocytoma, Endocr Relat Cancer, 17, 743, 10.1677/ERC-09-0118 · DOI
  9. Meyer-Rochow, 2010, MicroRNA profiling of benign and malignant pheochromocytoma identifies novel diagnostic and therapeutic targets, Endocr Relat Cancer, 17, 835, 10.1677/ERC-10-0142 · DOI
  10. John, 1999, Pheochromocytomas: can malignant potential be predicted?, Urology, 53, 679, 10.1016/S0090-4295(98)00612-8 · DOI · Paper page
  11. Amar, 2005, Genetic testing in pheochromocytoma or functional paraganglioma, J Clin Oncol, 23, 8812, 10.1200/JCO.2005.03.1484 · DOI · Paper page
  12. Brouwers, 2006, High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing, J Clin Endocrinol Metab, 91, 4505, 10.1210/jc.2006-0423 · DOI · Paper page
  13. Tippett, 1986, A re-evaluation of dopamine excretion in phaeochromocytoma, Clin Endocrinol (Oxf), 25, 401, 10.1111/j.1365-2265.1986.tb01706.x · doi:10.1111/j.1365-2265.1986.tb01706.x
  14. Proye, 1992, High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991, J Endocrinol Invest, 15, 651, 10.1007/BF03345810 · DOI
  15. Januszewicz, 2001, Dopamine and dopa urinary excretion in patients with pheochromocytoma – diagnostic implications, Blood Press, 10, 212, 10.1080/08037050152669729 · doi:10.1080/08037050152669729
  16. van der Harst, 2002, The value of plasma markers for the clinical behaviour of phaeochromocytomas, Eur J Endocrinol, 147, 85, 10.1530/eje.0.1470085 · DOI
  17. Eisenhofer, 2005, Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine, J Clin Endocrinol Metab, 90, 2068, 10.1210/jc.2004-2025 · DOI · Paper page
  18. Eisenhofer, 1986, Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase, Clin Chem, 32, 2030, 10.1093/clinchem/32.11.2030 · DOI · Paper page
  19. Lenders, 1993, Determination of metanephrines in plasma by liquid chromatography with electrochemical detection, Clin Chem, 39, 97, 10.1093/clinchem/39.1.97 · DOI · Paper page
  20. Rao, 2000, Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment, Hypertension, 36, 1045, 10.1161/01.HYP.36.6.1045 · DOI
  21. Amar, 2006, Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas, Ann NY Acad Sci, 1073, 383, 10.1196/annals.1353.042 · DOI
  22. Ayala-Ramirez, 2011, Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators, J Clin Endocrinol Metab, 96, 717, 10.1210/jc.2010-1946 · DOI · Paper page
  23. Remine, 1974, Current management of pheochromocytoma, Ann Surg, 179, 740, 10.1097/00000658-197405000-00029 · DOI · Paper page
  24. Proye, 1994, The pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist?, World J Surg, 18, 467, 10.1007/BF00353738 · doi:10.1007/bf00353738
  25. Goldstein, 1999, Clinical experience over 48 years with pheochromocytoma, Ann Surg, 229, 755, 10.1097/00000658-199906000-00001 · DOI · Paper page
  26. Mannelli, 1999, Pheochromocytoma in Italy: a multicentric retrospective study, Eur J Endocrinol, 141, 619, 10.1530/eje.0.1410619 · DOI · Paper page
  27. Edstrom Elder, 2003, The management of benign and malignant pheochromocytoma and abdominal paraganglioma, Eur J Surg Oncol, 29, 278, 10.1053/ejso.2002.1413 · doi:10.1053/ejso.2002.1413
  28. Amar, 2005, Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma, J Clin Endocrinol Metab, 90, 2110, 10.1210/jc.2004-1398 · DOI · Paper page
  29. Feng, 2011, Predictive factors for malignant pheochromocytoma: analysis of 136 patients, J Urol, 185, 1583, 10.1016/j.juro.2010.12.050 · DOI
  30. Park, 2011, Predictive characteristics of malignant pheochromocytoma, Korean J Urol, 52, 241, 10.4111/kju.2011.52.4.241 · DOI
  31. Timmers, 2008, Biochemically silent abdominal paragangliomas in patients with mutations in the Sdhb gene, J Clin Endocrinol Metab, 93, 4826, 10.1210/jc.2008-1093 · DOI · Paper page
  32. Timmers, 2007, Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma, J Clin Oncol, 25, 2262, 10.1200/JCO.2006.09.6297 · DOI · Paper page

Cited by

See all 334

Metadata

Authors
Eisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K., Timmers, H. J., & Pacak, K.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2012-07
Volume
48
Issue
11
Pages
1739-1749
ISSN
0959-8049
Cited by
334
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • European Union 7th Framework Program (HEALTH-F2-2010-259735)
  • Deutsche Forschungsgesellschaft

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. https://app.cochat.ai/papers/10.1016/j.ejca.2011.07.016
The paper
Eisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K., Timmers, H. J., & Pacak, K. (2012). Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2011.07.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.